The principal complication in replacement therapy for hemophilia A is the generation of autoantibodies (FVIII inhibitors) that occurs in about 30% of hemophilic patients after the infusion of plasma-derived or recombinant FVIII [28]. Here, F8 is linked to hemophilia A.